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INTRODUCTION 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 The incidence of breast cancer has been steadily increasing in India, 
keeping trend with global scenario, mostly contributed by the rapid economic 
development leading on to adoption of the western life styles. In a study by Yeole 
BB and Kurkure AP, there has been a significant leap in the incidence of breast 
cancer in India over the past two decades. Nearly 100,000 new cases of breast 
cancer are diagnosed in India every year and about 5% to 12% of them are young 
patients. At any given time there will be one million patients of breast cancer in 
India either on treatment or as survivors. The life time risk of developing breast 
cancer is 1:30 (incidence rate of 20 cases per 100,000) in Urban India and 1:65 
(incidence rate of 8.6 cases per 100,000) in rural India, reflecting the influence of 
life style on breast cancer incidence1, 55. 
 
 With the increase in awareness among general population, more and more 
patients present to their physicians at an early stage1. This along with the 
improvement in treatment modalities has resulted in an ever expanding population 
of breast cancer survivors, who are prone for long-term cancer treatment related 
complications including Poor Bone Health. 
 There has been a significant improvement in our knowledge regarding poor 
bone health among elderly subjects particularly, women at high risk6, However 
there is still paucity of information about the status of bone health among young 
premenopausal females particularly in India. These patients who either have 
chemotherapy associated premature menopause or have been rendered estrogen 
deficient2 (by castration) as a part of multimodal treatment, may be at a higher risk 
of osteoporosis and its complications. 
 
 This study is a sincere effort to determine the bone health of young 
survivors of breast cancer in India, so as to intervene at appropriate time and make 
a difference in their Quality Of Life. 
 
  
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
The aim of the study is, 
 
 To study the Bone Mineral Density in young breast cancer patients and 
 compare with matched controls. 
 
  
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 There has been increase in incidence of Breast Cancer World wide, and this 
combined with early detection and improvement in treatment modalities has 
resulted in significant improvement in survival of patients with breast cancer1. 
This ever expanding population of breast cancer survivors are increasingly prone 
for long-term treatment related complications. 
 
Impact on quality of life: One of the important long-term complications is 
significant bone loss, which entails an increased risk of fractures. As reported by 
Cooper C, the sites prone for fracture include neck of femur, vertebral spine 
particularly lumbar and radius among others2. These fractures are generally caused 
by trivial injury. Osteoporotic fractures drastically affect quality of life as are often 
associated with chronic pain and loss of mobility, making these patients 
dependent3. Ten to 20% of patients with fracture of neck of femur require long 
term hospital care after management of acute condition, while another 20% require 
assistance in coping with activities of daily living4. Similarly patients of fracture 
of spine have significant pain requiring significant medications as well as loss of 
work. 
 Therapy – induced damage to bone mass may rapidly become manifest, but 
it may also remain latent and become manifest later in life when it is supplemented 
by the age dependent processes of bone loss. As found by Barr RD and Simpson 
T, this is particularly seen in young survivors, in whom the cancer treatment may 
have had a deleterious effect on acquisition of peak bone mass5. 
 
 At present, most treating doctors including Medical Oncologists often see 
their patients at an advanced stage of poor bone health. This is unsatisfactory 
because the best treatment results can be achieved either by preventing the 
development of osteoporosis or in the early stage of disease2.  
 
Definition: Osteoporosis is defined as a reduction of bone mass (or density) or the 
presence of a fragility fracture. Loss of bone tissue causes deterioration in the 
architecture of the skeleton, the combination leading to a markedly increased risk 
or fracture6. 
 
Operational definition: On conventional X-ray, osteoporosis can only be 
recognized with certainty when bone loss is around 30% to 50%2. Hence 
Osteoporosis has been increasingly defined in terms of bone density. Bone 
Mineral Density (BMD) measurements are usually given as Standard Deviation 
(SDs) from the mean. In relation to the bone mass of 30 yr old subjects of the 
same sex, this SD value is expressed as a T score and in relation to an age-
matched population as Z-score6-7. 
 A World Health Organization (WHO) expert panel proposed that a T score 
of – 2.5 SD below the young adult mean value be considered as Osteoporotic and 
those with T scores between – 1 and – 2.5 SD be considered as Osteopenic2, 8. 
 
Factors affecting bone integrity in breast cancer survivors2, 9 
 
1. Hypogonadism 
a) Medical Castration. 
b) Surgical Oophorectomy. 
c) Radiocastration. 
d) Chemotherapy induced Ovarian Insufficiency. 
2. Endocrine Manipulation. 
3. Chemotherapy. 
 
Mechanism of bone loss due to hypogonadism 
 
 In both sexes, the sex hormones play a fundamental role in maintaining 
bone mass. Menopause (natural or iatrogenic) is particularly vulnerable time 
during which women undergo an accelerated, transient phase of bone loss. This 
accounts for about 20% to 30% of cancellous bone loss and 5% to 10% of cortical 
bone loss. This accelerated phase can be fully prevented by early intervention 
before it merges with an underlying late phase of slow bone loss and proves to be 
detrimental2.  
Role of Estrogens: Estrogens act through direct and indirect mechanism to 
restrain bone resorption.  The loss of this restraint in early menopause results in an 
increase in osteoclast formation and survival. At molecular level, estrogens 
interfere with the transcriptional regulation of a number of cytokines and cytokine-
related factors that influence the differentiation of osteoclast progenitors and 
osteoclast survival, such as interleukin-1, interleukin-6, tumor necrosis factor and 
osteoprotegerin10.  
 
 A pattern of bone loss similar to that seen after natural menopause also 
occurs in younger women with amenorrhoea caused by dysregulation of 
gonadotropin-releasing hormone (GnRH) and premature ovarian failure secondary 
to chemotherapy. Richelsen et al observed that Bone Mineral Density values in 
women who had been oophorectomized 20yrs earlier and in postmenopausal 
women who had been amenorrheic for a comparable period but were 20yrs older 
were similar and significantly lower than those in young, healthy premenopausal 
women11.  Cann et al demonstrated that women with premature ovarian failure 
have an average vertebral bone density of 21% below that of age matched 
eumenorrheic women12. 
 
 In addition estrogens play a vital role in achieving maximal bone mass 
during puberty. If gonadal dysfunction occurs during this time, peak bone mass is 
reduced and the person is susceptible to poor bone health later in life.  
Medical Oophorectomy: This is achieved by administration of Gonadotropin-
releasing hormone agonist. GnRH analogs continually stimulate the gonadotropic 
cells in the pituitary, thus quickly leading to downregulation of the Luteinizing 
hormone-releasing hormone receptors and thus to complete ovarian insufficiency2. 
This form of endocrine manipulation is effectively tried in premenopausal women 
with breast cancer. Johansen J, et al, noted in their study that GnRH therapy is 
associated with a marked decline in spinal bone density just after 6 months of 
therapy13. However on a positive note, Fogelman I, et al reported that there will be 
atleast partial recovery of BMD after 1 year of cessation of GnRH therapy14.  
 
Surgical Oophorectomy: This method is for permanent and complete ablation of 
ovarian function. Though not popular in the west now with the use of medical 
oophorectomy, it is still the cost effective method followed at many oncological 
centres in developing countries.  
 
Radiocastration: In few of the centres including Cancer Institute (WIA) 
radiotherapy is used for ablation of ovarian function in which 20 Gy of 
radiotherapy is delivered over a period of five days.  
 
Chemotherapy induced ovarian insufficiency (hypogonadism): Ovarian 
insufficiency generally develops with in 1 year of therapy in 63% to 96% of 
premenopausal women with breast cancer who receive postoperative adjuvant 
chemotherapy regimens, such as cyclophosphamide, methotrexate and 
flurouracil15 or doxorubicin, cyclophosphamide and flurouracil protocols2. 
 
Cyclophosphamide: It is the major cause of hypogonadism in these patients as a 
result of primary ovarian failure. Correspondingly, there is an increase in plasma 
luteinizing hormone (LH) and follicle stimulating hormone (FSH), indicating that 
chemotherapy affects the ovary itself and not the hypothalamus or pituitary. 
Adrenal function is also unaffected15. This has been confirmed by Charles LS, et al 
in their prospective study. The metabolite phosphoramide mustard is likely to be 
the culprit for ovarian toxicity of cyclophosphamide16. The dose of 
cyclophosphamide to cause permanent ovarian failure is dependent on age of 
patient. At 20yrs, 35yrs and 45 yrs the dose of cyclophosphamide to cause ovarian 
failure was 30gm, 10gm and 5gm respectively56. 
 
Pathogenesis: Studies in animals have shown that cyclophosphamide causes a 
dose dependent destruction of ovarian follicles and that primordial follicle are 
most sensitive, followed by antral and growing follicles2. Ataya K and Moghissi K 
proposed that, the Granulosa cells seem to be the primary ovarian target cells for 
cyclophosphamide. This effect involves alkylation of cell membrane and 
intracellular proteins and/or nuclear damage. Damage to the granulosa cells would 
affect the oocyte through the gap junctions known to connect the oocyte with its 
surrounding cumulus oophoricus granulosa cells17.  
 Most of the patients receiving chemotherapy (that includes 
cyclophosphamide) become amenorrheic during or within 2 to 4 months after the 
end of the chemotherapy.  As has been reported by Reichman BS, et al the risk of 
ovarian injury is related to the age of patient at the time of treatment, the 
cumulative dose of drug administered and the duration of treatment18. Temporary 
cessation of ovulation and menstruation result from damage to maturing follicles. 
Permanent effects occur when the number of surviving primordial follicles cannot 
sustain hormonal cyclicity. Amenorrhea frequently occurs in women over 40yrs 
(closer to their natural menopause) and is generally reversible in women less then 
30yrs, thus making age the most important determinant of ovarian function.15,19. 
 
 The fact that adjuvant chemotherapy will precipitate osteoporosis in breast 
cancer patients due to premature menopause is emphasized by Bruning et al, who 
observed 10% lower than age matched average BMD values in women who had 
become amenorrheic because of chemotherapy20. 
 
Endocrine Manipulation:  
 
 There are a number of endocrine treatment regimens in which a deliberate 
part of therapeutic strategy is premature ovarian insufficiency or the further 
reduction of circulating estrogen levels in women who have no ovarian function. 
Though the choice of endocrine agent is determined by multiple factors including, 
menopausal status, stage of disease, prognostic factors and toxicity profile of the 
agent, these manipulations are associated with considerable long-term risk of 
osteoporosis2, 21.   
 
Tamoxifen: This triphenyl derivative is the prototype of the Selective Estrogen 
Receptor Modulators (SERMs). At least two regions of the estrogen receptor are 
required for transcriptional activity: activating function-1, located near the amino 
terminus, and activating function-2, located within the ligand - binding domain. 
The ability to affect differentially the three-dimensional structure of the AF- 2 
region after ligand binding has been suggested to be an important mechanism that 
contributes to the selective actions of the SERMs22. Depending on the tissue, 
tamoxifen exhibits a range of biologic activity from full estrogen antagonism to 
partial agonism. Despite acting as a partial estrogen agonist on the skeleton, it 
causes bone loss in the spine and hip in premenopausal patients because it has a 
weaker effect than the genuine estrogens23, 24. 
 
Other SERMs: Several other SERMs are currently being evaluated for prevention 
and treatment of breast cancer along with their role in maintaining bone health, 
including Raloxifene25, Toremifene, Droloxifene, Idoxifene and Miproxifene26. 
Most of these agents in small studies have been found to improve upon bone 
health in osteoporotic postmenopausal patients, but the exact effect on bone 
particularly in premenopausal ladies needs to be studied in large randomized 
controlled studies. 
 
Pure Antiestrogens: Another concept of endocrine manipulation is pure 
antiestrogens also known as Estrogen receptor down-regulators such as 
Fulvestrant have been shown to be an effective after tamoxifen failure. These 
antiestrogens are entirely free of partial agonist activity. They block transcriptional 
activity via the estrogen receptor both by preventing the binding of estrogen 
receptor to DNA and by reducing the number of estrogen acceptors. The effects of 
pure antiestrogens on the skeleton are as expected not very favourable. As they 
exhibit no agonist activity, an accelerated bone loss similar to that observed in 
early menopause is seen in younger women27, 28. 
 
Aromatase Inhibitors: In postmenopausal women, the majority of the residual 
levels of circulating estrogens are derived from androgens, which are secreted by 
the ovaries and the adrenal cortex and converted to estrogens in peripheral tissues, 
such as fat and muscle. The conversion to estrone and estradiol occurs via three 
hydroxylation steps which are catalyzed by the cytochrome P – 450 hemoprotein 
aromatase. Aromatase inhibitors are therefore effective inhibitors of residual 
estrogens in postmenopausal women. Both steroidal substrate analogs, ie, type I 
inhibitors (which inactivate the enzyme), and nonsteroidal competitive reversible 
analogs, ie type II inhibitors, such as anastrozole and letrozole, are available29. 
These inhibitors suppress estrogen levels by more than 95% in postmenopausal 
women. 
 
 The findings of Heshmati and Cummings now have proved beyond doubt 
that even minuscule gradients of estradiol is capable of influencing BMD and 
fracture particularly in the elderly. They found that despite such low levels, serum 
sex steroids have a positive effect on bone modulation and suppressing this result 
in about 15% bone resorption30, 31. 
 
Chemotherapy:  
 
 Chemotherapeutic agents are known to have hormone independent effects 
on bone health2. Cytotoxic drugs commonly used in treatment of breast cancer and 
have been known to have a negative affect on bone modulation are, 
1. Cyclophosphamide. 
2. Methotrexate. 
3. Doxorubicin 
4. Taxanes 
 
Cyclophosphamide:  
 
 Treatment with cyclophosphamide has been associated with decrease in 
number of both osteoblasts and osteoclasts on the bone surface of the mandibular 
condyles and to cause osteopenia. These observations indicate that apart from its 
effects on the gonads, this agent may also have independent direct effects on bone 
metabolism2.  
Methotrexate: 
 
  Numerous therapy regimens in Oncology contain components that 
potentially have negative effects on bone metabolism independent of their effects 
on the sex hormone status. One such agent that has virtually been proven to have a 
causal role in osteopathy is methotrexate. The negative influence of methotrexate 
on bone mass seems to be due to an increase in bone resorption accompanied by 
inhibition of bone formation. As a result there is a massive uncoupling of bone 
turnover32. At cellular level it depletes reduced folates, which ultimately leads to 
an inhibition of DNA synthesis. This leads to reduced recruitment of osteoblastic 
cells from proliferative precursor cells, whereas it does not seem to affect 
osteoblast differentiation. Animal studies have shown that, methotrexate in a dose- 
responsive manner influences matrix mineralization33, 34. 
 
 Some, albeit not all, studies have also shown an increase in bone resorption, 
as assessed by both increases in urinary hydroxyproline levels and 
histomorphometry. The lack of inhibitory effects on osteoclast numbers in contrast 
to osteoblast numbers may be due lower toxicity of osteoclast precursors to this 
agent, perhaps because of differences in the accumulation and exchange rate of 
this drug in different tissue compartments35. Several groups have reported severe 
osteoporosis with fractures in the course of long-term therapy with methotrexate. 
However, subclinical disease may be much more common. The osteopenia seemed 
to be at least somewhat reversible after the drug was discontinued. It is not clear as 
to what extent adjuvant corticosteroid therapy played a role2. 
 
Doxorubicin:  
 
 Doxorubicin has been observed to cause a decrease in the trabecular bone 
volume in animal studies. The bone formation rate was also profoundly 
diminished by nearly 60%. Together, these findings suggest that doxorubicin has 
profound inhibitory effects on bone formation. The clinical relevance of these 
bone cell effects on human bone mass is unknown2. 
 
Taxanes:  
 
 Nabholtz JM, et al have reported that taxanes particularly docetaxel causes 
premature menopause when used in adjuvant setting in combination with 
cyclophosphamide and doxorubicin. However this effect was independently 
attributed to taxanes36. 
 
 Ifosfamide, interferon-alfa and glucocorticoids are the other agents used in 
cancer therapy which are significantly associated with negative bone health. 
Conventional risk factors:  
 
 Apart from the above mentioned breast cancer specific risk factors, women 
are also prone for and subsequently to fracture, due to the presence of 
conventional risk factors like any other individual. These factors include6, 15, 37, 
 
A. Nonmodifiable risk factors 
 1. Personal history of fracture as an adult. 
 2. History of fracture in first degree relative. 
 3. Female sex. 
 4. Advanced age. 
 5. Asian race 
 
B. Potentially modifiable risk factors 
 1. Poor nutritional status. 
 2. Low body weight. 
 3. Low Calcium and Vitamin D intake. 
 4. Current cigarette smoking. 
 5. Alcoholism. 
 6. Inadequate physical activity. 
 7. Chronic diseases and Metabolic bone diseases. 
 8. Drugs like steroids, lithium, heparin etc. 
 
Nutritional status:  
 
 Subjects with poor nutritional status will have deficiencies, which not only 
include calcium and vitamin D, but also essential amino acids, trace minerals etc. 
The end result is poor bone remodelling, in that bone resorption is more then new 
bone formation. As already known, risk of osteoporosis depends on peak bone 
mass which is achieved in adulthood, and if nutritional status is poor by any 
means, subsequently the peak bone mass attained is also sub-optimal6, 14. 
 
Calcium intake: 
 
 Apart from its role in attaining peak bone mass described above, calcium 
insufficiency induces secondary hyperparathyroidism, leading to bone resorption. 
Though this is a good short term measure to maintain calcium homeostasis, in long 
term it is detrimental to bone health. The recommended daily intake of calcium is 
1000 to 1200mg for adults38. Similarly vitamin D deficiency also contributes to 
poor bone health and the daily recommended dose is 100 IU39 in healthy general 
population and 400 to 800 IU in people at risk37. 
 
 
Physical inactivity:  
 
 Inactivity such as prolonged bed rest or paralysis results in significant bone 
loss. Evidence now suggests that chronic high level of physical activity has a 
positive affect on bone mineral density. It has also been found that people 
involved in moderate exercise in childhood and through adulthood have lesser risk 
of fracture and better peak bone mass6. 
 
Low body weight:  
 
 Subjects with low body weight have high chances of poor bone health 
mostly due to suboptimal attainment of peak bone mass. Patients with poor 
nutritional status are likely to have low body weight and vice versa. In summary, 
poor bone health is the end result of poor nutritional intake leading on to low body 
weight and then finally ending up with osteoporosis and its consequences6. 
 
Chronic Diseases:  
 
 Various genetic and acquired diseases are associated with an increased risk 
of osteoporosis including thyrotoxicosis, hyperparathyroidism, cushing’s 
syndrome, diabetes mellitus, acromegaly, chronic liver and renal diseases etc. 
Mechanisms that contribute to bone loss is an inter play of multiple factors 
including nutrition, reduced physical activity and use of medications. 
Cigarette smoking:  
 
 Use of cigarettes over long period  has detrimental effects on bone mass. 
These effects are mediated directly by toxic effects on osteoblasts and indirectly 
by modifying estrogen metabolism. Smokers reach menopause 1 to 2 yrs earlier 
and are also prone for recurrent respiratory illness, frailty, and decreased exercise 
potential6. Similarly alcoholics have poor bone health due to direct effect on 
osteoblast, poor nutritional intake and the added risk of fall and fracture.  
 
Management of bone health in breast cancer survivors:  
 
 Identification of high risk patients: Women with breast cancer diagnosis are 
at increased risk for osteoporosis and fracture. In one study by Kanis JA, et al it 
was reported that the presence of even localized breast cancers influenced fracture 
risk. Vertebral fracture risk was greater in breast cancer patients with resected, 
localized disease (odds ratio [OR], 4.7; 95% CI, 2.3 to 9.9) and 23 times greater in 
breast cancer patients with soft tissue metastasis without evidence of bone 
metastasis (OR, 22.7; 95% CI, 9.1 to 57.1) compared with women with no 
cancer40.  
 
 
However as per ASCO definition37, 6, high risk is 
1. All women with age >65 years 
2. All women with age 60-64 years with one of the following 
a. family or personal history of fracture 
b. body weight <58 kg 
c. any of the other risk factors described above 
3. Postmenopausal lady of any age receiving aromatase inhibitors 
4. Premenopausal lady with therapy associated premature  menopause 
or having iatrogenic estrogen deficit status. 
 
 If the patient is at high risk for poor bone health, it is recommended to 
proceed with measurement of bone mineral density and define the status according 
to WHO definition described earlier. 
 
Measurement of bone mass:  
 
 The techniques approved by FDA for estimating skeletal mass or density 
includes6,  
 
1. Dual energy X-ray absorptiomety (DXA) 
2. Single-energy X-ray absorptiometry (SXA) 
3. Quantitative computed tomography (CT) and  
4. Ultrasound. 
Dual energy X-ray absorptiomety: 
 
 DXA is a highly accurate X-ray technique and is the standard for measuring 
bone density in most cancers.  Though it can be used for measurements of any 
skeletal site, clinical determinations are usually made from the lumbar spine and 
hip.  Portable DXA machines have been developed that measure the heel 
(calcaneus), forearm (radius and ulna), or   finger (phalanges).  
 
Computed Tomography: (CT) 
 
 CT is used primarily to measure the spine, and peripheral CT is used to 
measure bone in the forearm or tibia.  Research into the use of CT for 
measurement of the hip is ongoing.  The results obtained from CT are different 
from all others currently available since this technique specifically analyzes 
trabecular bone in vertebrae, eliminating posterior cortical elements of the spine, 
and can provide a true density (mass of bone per unit volume) measurement.  
However, CT remains expensive, involves greater radiation exposure, and is less 
reproducible. 
 
Ultrasound: 
 
 Ultrasound is used to measure bone mass by calculating the attenuation of 
the signal as it passes through bone or the speed with which it traverses the bone.  
It is unclear whether ultrasound assesses bone quality, but this may be an 
advantage of the technique.  Because of its relatively low cost and mobility, 
ultrasound is amenable for use as a screening procedure44, 45. In a study conducted 
by Kang et al, it was found that this method of measurement of BMD is 
comparable to DEXA44 and has been approved by US FDA for measurement of 
BMD. The procedural details of using this machine is mentioned in the section 
Patients and Methods. 
 
 The hip is the preferred site of measurement in most individuals, since it 
predicts the risk of hip fracture, the most important consequence of osteoporosis, 
better than any other bone density measurement site.  When hip measurements are 
performed by DXA, the spine can be measured at the same time.  In younger 
individuals, such as perimenopausal or early postmenopausal women, spine 
measurements may be the most sensitive indicator of bone loss6. 
 
Osteoporosis prevention:  
 
 Most women with newly diagnosed breast cancer are at risk of osteoporosis 
either due to age or as a result of cancer treatment. Low BMD and history of 
fracture are two of the strongest fracture risk factors. One SD decrease in hip BMD 
is associated with a 2.6-fold increase in hip fracture risk41. The 5-year absolute risk 
of a vertebral fracture (t score = -2.5) is about 8%; this increases to about 15% 
over next 20 years. Women with a prevalent vertebral fracture are two to four 
times more likely to experience a new vertebral fracture and twice as likely to 
experience a hip fracture42. Thus as in any field of medicine, “Prevention is better 
than Cure”. 
Recommendations for osteoporosis screening: 
 
 The United States Preventive Services Task Force (USPSTF) recommends 
BMD screening for all high risk patients as mentioned above, but does not 
recommend routine screening for low risk subjects43. 
 
General principles of osteoporosis prevention and therapy: 
 
 Preventing osteoporotic fractures can be achieved by maximizing peak 
skeletal mass, preventing or slowing rates of bone loss, and preventing falls. 
Fundamental measures for bone health include adequate calcium intake (1,200 
mg/d), and vitamin D intake (400 to 800 U), exercise, and avoidance of smoking. 
Women who should receive osteoporosis therapy include those with prior fragility 
fractures, as well as women with a BMD t score -2.543. Treatment of women 
without fractures but who have borderline low BMD (t score < -1.0) and other risk 
factors is controversial and should be decided on an individual basis.  
 
 The Osteoporosis Research Advisory Group (ORAG) has provided a 
comprehensive review of the randomized trials of osteoporosis therapies46. 
Vitamin D (hydroxylated), calcitonin, raloxifene, the bisphosphonates, etidronate, 
risedronate, and alendronate all reduced vertebral fractures with the strongest data 
supporting alendronate and risedronate. Only alendronate and risedronate 
significantly reduced nonvertebral fractures. The particular issues relevant to 
women with breast cancer are summarized in Table 1. In postmenopausal women, 
tamoxifen had modest influence on BMD and fracture risk, but is not considered a 
stand-alone osteoporosis therapy. Raloxifene is approved for osteoporosis 
prevention and therapy exclusively in postmenopausal women but clinicians have 
reservations about its efficacy47. Other agents also influence fracture risk and 
include tibolone, strontium, and bisphosphonates clodronate, ibandronate, 
pamidronate, tiludronate, and zoledronic acid. Few recent studies including 
randomized trials have shown the beneficial effects of zoledronic acid48, 
clodronate and ibandronate in reversing osteoporosis and improving BMD.  
 
 After the ORAG report was released, teriparitide46, a synthetic parathyroid 
hormone, was approved for osteoporosis therapy. However, because this drug was 
associated with osteosarcoma development in animal studies, it is not 
recommended for use in women with diagnosed breast cancer37. 
 
 
 
 
 
Table 1. Therapies Available for Osteoporosis Prevention and Therapy: Approved by US FDA 
Therapy Dosage Common Side Effects 
Issues for Use in Breast Cancer 
Patients 
FDA approved Bisphosphonates 
Alendronate 5 mg PO daily Upper GI irritation, myalgias and 
arthralgias 
None 
Prevention and 
treatment 
35 PO weekly     
  10 mg PO daily o     
  70 PO weekly     
Risedronate     None 
Prevention and 
treatment 
5 mg PO daily or     
  35 PO weekly     
Selective Estrogen Receptor Modulator 
Raloxifene 
Prevention and 
treatment 
60 mg PO 
daily 
Common: Hot flashes, leg 
cramps; rare: deep vein 
thromboses 
Cross resistance with tamoxifen; 
not recommended after tamoxifen 
Parathyroid Hormone (synthetic) 
 Teriparitide 20 U SQ daily Common: dizziness, leg cramps; 
rare: hypercalcemia 
Not recommended; Should not be 
used in patients at increased risk of 
bone metastases or hypercalcemia 
(due to osteosarcoma development 
in animal models) 
Estrogen plus 
progestin 
combination 
Varies     
Five combination agents 
Prevention only   Common: breast tenderness, 
vaginal bleeding; life 
threatening: CHD, stroke, PE, 
breast cancer 
Not recommended in patients with 
a breast cancer diagnosis when 
used for osteoporosis prevention 
Estrogens 
Nine agents 
Prevention only Varies Common: breast tenderness, 
vaginal bleeding; life 
threatening: CHD, stroke, PE, 
breast cancer 
Not recommended in patients with 
a breast cancer diagnosis when 
used for osteoporosis prevention 
Calcium 1200 mg/d Constipation, bloating, gas None 
Vitamin D 400–600 mg None None 
Calcitonin nasal 
spray 
200 U one 
nostril/day 
Rhinitis None 
Abbreviations: FDA, Food and Drug Administration; PO, orally; SQ, subcutaneous; GI, gastrointestinal; CHD, 
coronary heart disease; PE, pulmonary embolism. 
Premenopausal therapy: 
 
 Regardless of receptor status, many premenopausal women are at risk of 
chemotherapy associated premature menopause, which results in rapid bone loss 
comparable to that seen with surgical oophorectomy (7.7% loss in lumbar spine 
BMD in one report)49. Concurrent tamoxifen use in this setting may not be 
protective since some studies have suggested that tamoxifen itself is associated 
with loss of bone density in premenopausal women. 
 
Bisphosphonates in combination with adjuvant therapy in breast cancer patients 
without bone metastases: The effect on BMD of bisphosphonates with hormonal 
or cytotoxic chemotherapy is being evaluated in comparative trials. In a small trial 
of 120 postmenopausal breast cancer patients without skeletal metastases, women 
were randomly assigned to one of two (SERMs), either tamoxifen or toremifene 
and, in a factorial design, had a second randomization to oral clodronate 1,600 mg 
daily or control (no bisphosphonate). At 2 years, clodronate together with a SERM 
markedly increased lumbar spine BMD by 2.9% (P = .001) while patients 
receiving the SERM alone did not significantly increase BMD50. 
 
 For patients given adjuvant CMF chemotherapy, significantly less BMD 
loss occurred in women randomly assigned to oral clodronate compared with 
placebo51. Currently, there are only few reports on the efficacy of oral 
bisphosphonates for osteoporosis therapy. However ibandronate has been 
approved for this purpose. In a randomized trial of 52 patients, the bisphosphonate 
risedronate taken as 30 mg per day for 2 weeks followed by 10 weeks of no drug 
was shown to prevent bone loss in young women with breast cancer and premature 
chemotherapy induced menopause52.  
 
 In a promising preliminary report, premenopausal breast cancer patients 
receiving goserelin plus anastrozole or goserelin plus tamoxifen were randomly 
assigned to the bisphosphonate zoledronic acid (4 mg IV q 6 months) or placebo. 
After 6 months, those receiving zoledronic acid had significantly higher lumbar 
spine BMD (P < .0001). Currently, there are no reports on the use of calcium and 
vitamin D in breast cancer patients free of bone metastases53.  
 
Bone health summary37: In otherwise healthy women, a strong body of evidence 
supports a strategy of early detection and therapy of osteoporosis. Similar 
recommendations can be applied to breast cancer patient management, as shown in 
Figure 1 
 
 
 Figure 1 
Breast Cancer Patient 
Screened for Osteoporosis Risk 
                 High Risk 
 
9 All Women age >65 years 
9 All Women age 60-64 yrs with 
o Family history 
o Body weight<58 kg 
o Prior non-traumanatic 
fracture  
o Other risk factors 
        Postmenopausal women of any           
age receiving aromatase inhibitors 
 
9 Premenopausal women with 
therapy associated premature 
menopause 
High Risk 
Low Risk 
Screening for BMD Recommended 
DEXA of Hip - spine 
Screening for BMD 
Not Recommended 
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Begin therapy 
Alendronate or 
Ibandronate or 
Risedronate or 
Zoledronic acid or 
Raloxifene 
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Monitor Annually 
for Risk Status by 
History 
Repeat BMD, Annually Repeat BMD, 
Annually 
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Annually 
Future directions:  
 
Treatment related bone loss: 
 
 Irrespective of bone metastases, it is possible that all early stage breast 
cancer patients could benefit from bisphosphonates in the form of preservation of 
bone density. Adjuvant aromatase inhibition in postmenopausal patients and 
ovarian suppression in premenopausal patients are the subjects of ongoing studies.  
 
 The final report of the Austrian Breast Cancer Study Group randomized 
trial of zoledronic acid in premenopausal women treated with hormonal therapy is 
eagerly anticipated.  
 
 The international pharmaceutical company-sponsored Zometa/Femara 
Adjuvant Synergy Trial study is an open-label, randomized, multicenter study 
evaluating the use of zoledronic acid in the prevention of cancer treatment-related 
bone loss in postmenopausal breast cancer patients receiving letrozole as adjuvant 
therapy54. The International Breast Cancer Intervention Study II comparing 
anastrozole to placebo in women at high risk of developing breast cancer, and 
tamoxifen to anastrozole in ductal carcinoma in situ, has subprotocols including a 
bisphosphonate examining the effects of risedronate on prevention of bone loss 
associated with anastrozole. CALGB protocol 79809 is a phase II trial of 
intravenous zoledronic acid for the prevention of bone loss among localized breast 
cancer patients with chemotherapy-induced ovarian failure.  
 
Osteoclast targeted therapies: 
 
 Additionally, nonbisphosphonate compounds that interfere with bone 
metabolism are under investigation in breast cancer patients with bone metastases. 
Agents of interest include anti-RANK ligand pathway-targeted therapy, and anti-
parathyroid hormone-related peptide antibodies37.  
 
  
  
 
 
 
 
 
PATIENTS AND METHODS 
 
 
 
 
 
PATIENTS AND METHODS 
 
 
 
 
 The present study was conducted at Cancer Institute (WIA), Chennai. A 
total of 70 subjects were included in this prospective case control study, with each 
group consisting of 35 subjects. 
 
Inclusion criteria:  
 
For Patients:  
 
1. Patients diagnosed as carcinoma breast based on histopathology of 
invasive carcinoma between 1993-2005.  
2. Patients treated with multimodality therapy. 
3. Patients younger than or equal to 30 years at the time of diagnosis. 
4. Patients who have completed 2 years of follow up. 
5. Patients who underwent castration or had chemotherapy related 
amenorrhoea for more than 12 months56. 
 
For Controls: An equal number of age and sex matched healthy controls. 
 
Exclusion criteria:  
 
1. Patients with metastatic disease. 
2. Patients who continue to menstruate. 
3. Patients with other risk factors for osteoporosis like steroid intake, 
rheumatoid arthritis, chronic renal failure and metabolic bone disease. 
Methodology:  
 
 Thirty five patients of breast cancer who fulfilled the inclusion and 
exclusion criteria were registered into the study as cases. These patients had 
received multimodal therapy as per the Institute protocol. These individuals were 
subsequently assessed as per the protocol of the study. This includes recording 
their present age, duration of follow up, height, weight, type of adjuvant treatment, 
duration of castration/amenorrhoea and measurement of Bone Mineral Density. 
All the individuals also underwent baseline investigations with haemogram, renal 
function tests, liver function tests, blood sugar level and serum calcium. 
 
 Similarly age and sex matched healthy controls were chosen from the 
attendees accompanying the patients and were subjected to above mentioned tests 
including BMD. 
 
Measurement of Bone Mineral Density44: 
 
 BMD was measured using Ultrasound Bone Densitometer CM-100 
manufactured by Furuno Electric Co. LTD Japan45, with following specifications, 
 
 Measurement Site: Heel (calcaneus) 
 Measurement method: Ultrasound pulse penetration 
 Measuring parameter: Speed of sound 
 Ultrasound frequency: 500 kHz 
 Measurement time: approx 10 seconds. 
 
Procedure: The CM-100 is a bone densitometer using ultrasound to measure 
speed of sound (SOS) in the heel and contributed to screening and diagnosis of 
osteoporosis. First the gel was applied to heel and the foot was positioned on the 
foot rest on machine. The cylinder was aligned so that the foot set properly on the 
foot rest. After pressing the start key, over the next 10 seconds the result was 
printed based on speed of sound. 
 Normal if SOS > 1514m/s 
 Osteopenia if SOS is between 1514m/s and 1479m/s 
 Osteoporosis if SOS is < 1479m/s44. 
 
Statistical Analysis:  
 
 Descriptive statistical analysis has been carried out on the basis of analysis 
of the results of the study. Chi-square and Fisher Exact test were used to test the 
level of significance of BMD between the groups. Pearson Correlation was used to 
find the significance of study parameters with BMD. 
 
 The statistical software SPSS 15.0, Stata 8.0, MedCalc 9.0.1 and Systat 
11.0 were used to analyse data. 
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RESULTS AND OBSERVATIONS 
 
 
 
 
Table 1: Distribution of age at diagnosis among cases 
 
Age (years) Number % 
25-26 5 14.3 
27-28 8 22.9 
29-30 22 62.9 
Total 35 100.0 
Mean ± SD 28.57 ± 1.74 
 
Table 2: Distribution of present age among cases and controls 
 
Cases Controls 
Age(years) 
No % No % 
Up to 30 years 2 5.7 2 5.7 
31-35 years 23 65.7 20 57.1 
36-40 years 8 22.8 12 34.3 
41-45 years 2 5.7 1 2.9 
Total 35 100.0 35 100.0 
Mean ± SD 34.31±3.02 34.60 ±3.07 
 
 
Table 3: Duration of follow up among cases 
 
Duration of follow-up Number % 
< 3 years 5 14.3 
3–6 years 20 57.14 
> 6 years 10 28.57 
Mean ± SD 5.69 ± 3.10 
 
 
Table 4: Distribution of duration of AE* therapy 
 
Duration of AE(years) Number % 
2.00 - 3.00 7 20.0 
3.01 - 4.00 8 22.9 
4.01 - 5.00 11 31.4 
Completed 5 yrs 9 25.7 
Total 35 100.0 
Mean ± SD 4.34 ± 1.57 
 
* AE-Antiestrogen  
 
 
  
Figure 1: Distribution of patients with Castration and Chemo amenorrhea 
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Figure 2: Duration of follow up after Castration and Chemo amenorrhea 
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Table 5: Distribution of Bone Mineral Density (BMD) among cases and 
controls 
 
Cases Controls 
BMD(t-score) 
No % No % 
P values 
<-2.5 7 20.0 1 2.8 0.055 
-2.5 to -1.1 15 42.9 5 14.3 0.008 
>-1.0 13 37.1 29 82.9 <0.001 
Total 35 100.0 35 100  
Mean ± SD -1.41 ± 1.25 -0.22 ±0.98  
 
Table 6: Distribution of BMI among cases and controls 
 
Cases Controls 
BMI(kg/m2) 
No % No % 
Up to 20 2 5.71 3 8.57 
21-25 18 51.43 18 51.43 
26-30 11 31.43 11 31.43 
31-35 4 11.43 3 8.57 
Total 35 100.0 35 100.0 
Mean ± SD 25.11 ± 3.53 24.66 ±3.56 
 
 r= -0.352; P=0.038*
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Figure 3: Correlation between BMD and Age at follow up 
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Figure 4: Correlation between BMD and Duration of Follow up: 
 Table 7: Comparison of BMD among chemotherapy schedules 
 
FAC* CMF** 
BMD(t-score) 
No % No % 
P values 
<-2.5 2 13.33 5 25.0  
-2.5 to -1.1 7 46.67 8 40.0  
>-1.0 6 40.0 7 35.0  
Total 15 100.0 20 100  
Mean ± SD -1.35±1.05 -1.46±1.4 0.80 
 
 * Adriamycin, Methotrexate, 5-flurouracil 
 **Cyclophosphamide, Methotrexate, 5-flurouracil 
 
Table 8: Comparision of BMD among patients with castration and chemo 
amnorrhea. 
Castration Chemoamenorrhea 
BMD(t-score) 
No % No % 
P values 
<-2.5 5 19.23 2 22.22  
-2.5 to -1.1 12 46.15 3 33.33  
>-1.0 9 34.62 4 44.45  
Total 26 100.0 9 100  
Mean ± SD -0.77±1.82 -1.63±0.94 0.25 
  Thirty five patients of Breast Cancer and an equal number of matched 
healthy controls were included in the study.  
 
 Age at Diagnosis (Table 1): The mean age at diagnosis of patients was 
28.57 years and majority of the patients were in the age group of 29-30 years when 
a diagnosis of carcinoma of breast was made. 
 
 Present age (Table 2): The present age of patients (age at time of BMD) 
was statistically similar to the age of controls and hence both the groups were 
comparable. 
 
 Duration of follow up (Table 3): The median duration of follow up was 
4.5 years, with majority of patients having a follow up in the range of 3 years to 6 
years. 
 
 Duration of Antiestrogen(AE) therapy (Table 4): The median duration 
of antiestrogen therapy was 4.42 years with 57.1% of them taking it for more than 
4 years. Tamoxifen was the only AE used among all cases. 
 
 Distribution of patients with Castration and Chemo amenorrhea 
(Figure 1): Of the thirty five patients, 22 (62.85%) has surgical castration in the 
form of bilateral salphingo oopherectomy, 3 (8.58%) had radiocastration, while 
only one patient was on GnRH. Nine patients (25.72%) had chemo amenorrhea. 
Of the 15 patients on FAC, 3(20%) developed chemo amenorrhea and of the 20 
patients on CMF 6 (30%) developed chemo amenorrhea. However this difference 
was not statistically significant. 
 
 Duration of followup after Castration & Chemoamenorrhea(Figure2): 
The mean duration of follow up was 5.56 years (± 3.17) with almost 55% of 
patients having a follow up of 4 years and beyond.  
  
 Bone Mineral Density (Table 5): The mean BMD was -1.41 among cases 
which falls into Osteopenic range while it was -0.22, among controls which was 
normal. This difference was highly statistically significant. Nearly 63% of patients 
had poor bone health as compared to only 17% among controls. 
 
 Correlation between BMD and Age at follow up (Figure 3): There was a 
statistically significant inverse correlation between age of the patient and BMD (P-
0.03) which means more the age of the patient, lower is the BMD. The r value was 
-0.35 by Pearson correlation. 
 
 Correlation between BMD and Duration of Follow up (Figure 4): As 
the duration of follow up increased patients tend to have poorer bone health and 
this correlation was also statistically significant with P-value of 0.009 and r value 
of -0.43. Of the patients with more than 5 years of follow up (n=15) 6 (40%) had 
osteoporosis and 7 (46.67%) had osteopenia.  
 
 BMD among the chemotherapy schedules (Table 7): Although there was 
a trend towards poor bone health in patients receiving CMF as compared to FAC, 
this was not statistically significant. 
 
 Comparison of BMD among patients with castration and chemo 
amenorrhea (Table 8): There was no statistically significant difference in Bone 
Mineral Density between Castrated and Chemo amenorheic patients with a P-
value of 0.25. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     DISCUSSION  
DISCUSSION 
 
 
 
 
 In our study of bone mineral density among young patients of breast 
cancer, we tried to look at the bone health of these young patients. Of the 35 cases, 
7 (20%) were found to be osteoporotic and another 15 (42.9%) were osteopenic, 
this when compared to controls had only one (2.8%) subject with osteoporosis and 
5 (14.3%) subjects with osteopenia. Our results not only revealed that, nearly 63% 
of patients had poor state of bone health but also that bone mineral density 
worsened with the duration of follow up. 
 
 The detailed discussion of the observations and results in our study are as 
follows. 
 
Demographic profile: 
 
 Age: The mean age of patients at diagnoses was 28.57 ± 1.74, since the 
study was limited to patients with less than 30yrs age at diagnoses. As  found in 
various studies and in Surveillance, Epidemiology, and End Results (SEER) data 
and a study by Yeole BB et al in India, the incidence of breast cancer in the age 
group of 20-29yrs is less than 1% and that of 30-39 yrs is 6.5% to 10%55, 57.  
 The mean age of the patients at the time of last follow up (when BMD was 
done) was 34.31±3.02 years. Two patients (5.7%) were more than 40 yrs while 
nearly 65.7% (23) of were in the range of 31-35yrs. The mean age among controls 
was 34.31±3.02 yrs and both the groups were statistically comparable. The 
importance of age in these young patients who receive adjuvant therapy is that, it 
perfectly correlates with chemotherapy induced amenorrhea. In a study by 
Shapiro, et al they found that more the age of the patients, lesser is the chance for 
retaining menstrual function49 and amenorrhea is always almost irreversible in 
women over age 30 years19. In addition, patients with increasing age, tend to have 
natural bone loss resulting into a poorer bone mass14. 
 
Duration of follow up:  
 
 The mean duration of follow up among cases was 5.69 ± 3.10 yrs with 10 
patients (28.57%) being followed for more than 6 yrs after the end of protocol 
with multimodality therapy. As per a study done by Fogelman I, Blake GM, et al 
as the period after adjuvant therapy increases more and more patients become 
amenorrheic. In there study the incidence of amenorrhea was 60.5%, 69.4% and 
76.5% at 6 months, 2years and 3years respectively after adjuvant therapy14. 
 
Duration of Anti-estrogen therapy:  
 
 The mean duration of Anti-estrogen therapy in our study was 4.34 ± 1.57, 
with 9 (25.7%) patients completing the scheduled five years of adjuvant tamoxifen 
and another 11 (31.4%) patients had taken for more than 4 years. As per institute 
protocol, all the patients were on tamoxifen only. While tamoxifen prevents bone 
loss in postmenopausal women, it has opposite effect in premenopausal females. 
According to a study by Leena V, Inkeri E, et al, at 3 yrs follow up  
premenopausal women on tamoxifen had a mean bone loss of -4.6% while 
postmenopausal females had a stable BMD or reduced bone loss as compared to 
controls58. However in our study there was no statistically significant correlation 
between BMD and duration of anti-estrogen therapy. 
 
Castration and Chemotherapy induced amenorrhea: 
 
 Out of 35 patients in our study, 22 (62.85%) patients had surgical 
castration, 3  had radio castration, one  had medical castration with GnRH and 9 
(25.72%)  had chemo amenorrhea. 20% of patients on FAC and 30% of patients 
on CMF developed chemo amenorrhea, but this difference was not statistically 
significant. As reported by Shapiro CL, Manola J, et al 63% to 85% of patients on 
CMF and more than 50% of patients on FAC develop permanent chemo 
amenorrhea49. Almost all the patients with amenorrhea lasting for more than 12 
months never regained menstrual functioning56. 
Duration of follow up after Castration and Chemo amenorrhea:  
 
 The mean duration of follow up after patient had iatrogenic menopause was 
5.56 years (± 3.17) with almost 55% of patients having a follow up of 4 years and 
beyond. The relevance of follow up after patients had iatrogenic ovarian failure is 
stressed in a study by Cummings SR et al, who reported that castrated patients, if  
osteoporotic, have a 8% increased risk of  vertebral fractures at 5 years which 
increases to 15% at 20 years41. In our study of the 15 patients with more than 5 yrs 
of follow up, 6 (40%) were osteoporotic and 7 (46.67%) were osteopenic. Thus 
nearly 87% of the study population post 5 yrs of iatrogenic menopause was at risk 
of fragility fractures. 
 
Bone Mineral Density (BMD) among cases and controls:  
 
 The mean BMD among cases was -1.41 ± 1.25 and that among controls was 
-0.22 ±0.98 and this difference was statistically significant. Twenty percent of 
patients (N=7) were osteoporotic as compared to 2.8% (N=1) among controls. 
Similarly, 42.9% (N=15) cases and 14.3% (N=5) of controls were osteopenic. All 
these differences are statistically significant. According to a study in India by 
Sharma et al, the incidence of osteopenia among young adults between 35-44 yrs 
is 15.51%59. Similarly, Lin JD reported that incidence of osteopenia in the age 
group of 21-30 yrs is 8% and in 31-40 yrs is 10%, while the incidence of 
osteoporosis is 1% in both groups60. Leena V et al have reported that on an 
average, 7% of BMD is lost within one year and this rate is similar in patients with 
chemo amenorrhea as well as surgical castration58. 
 
BMI and weight among cases and controls:  
 
 Body mass index and weight were statistically similar between cases and 
controls. In our study, neither BMI nor weight had correlation with bone mineral 
density. Few studies have reported significant correlation between weight and 
BMI. Lesser the weight (<58 kg), more is the risk of osteoporosis and subsequent 
fractures6, 37. 
 
Correlation between BMD and Age at follow up:  
 
 In our study there was a statistically significant correlation between age of 
the patient and bone mineral density (P-value of 0.03). As the age of patient 
increased, there was worsening of bone density. Fogelman I, Blake GM, et al, 
have reported that BMD loss at lumbar spine was -4.5% to -8.2% at end of one 
year, -6.5% to -10.5% at end of two years and -6.2% to -7.2% in the third year14. 
Thus, as in our study with each increasing year, there was loss of BMD. Similarly 
Richelsen et al have reported that oophorectomized women had bone mineral 
density similar to postmenopausal women 20 years older and this detoriated with 
further follow up11. 
 
Correlation between BMD and Duration of Follow up: 
 
 In our study there was a significant statistical correlation between fall in 
bone density with increasing duration of follow up as well as increasing duration 
of ovarian insufficiency. In a study reported in Osteoporosis International14 there 
was 20% decline in bone mass over a period of 10 yrs and this was contributed by 
both iatrogenic menopause as well as age related changes like decreased physical 
activity, poor nutritional state, coexistence of co-morbid conditions and use of 
medications which can erode bone mass. 
 
Comparison of BMD among chemotherapy schedules: 
 
 In our study, the mean BMD was -1.35±1.05 among 15 patients who 
received FAC as compared to -1.46±1.4 among 20 patients who received CMF. A 
total of 9 patients (60%) in the FAC sub-group had poor bone density as compared 
13 (65%) in the CMF arm. Though there was a trend towards negative bone health 
among CMF patients, this did not reach statistical significance. As per the 
literature, patients with CMF have 30% to 80% more risk of becoming 
amenorrheic as compared to anthracycline based chemotherapy15 and hence have a 
higher risk of becoming osteoporotic. In an article by Johannes P and Diel IJ, 
cyclophosphamide causes osteoporosis indirectly by inducing ovarian failure 
while methotrexate has direct effect on bone which has been described as 
methotrexate osteopathy. Role of anthracyclines in humans to affect bone 
metabolism is not clear2. 
Comparison of BMD among patients with castration and chemo amenorrhea:  
 
 Among the 26 patients who underwent castration, 17 (65.38%) had poor 
bone health as compared to 5 (55.55%) patients who had chemotherapy induced 
loss of menstrual function. The mean BMD between these two groups was not 
statistically significant. Leena V, Elomaa I et al have reported that the decrease in 
BMD during first year is similar to that of surgically castrated patients58. However 
Fogleman I, et al, have reported that in patients with medical castration (GnRH) 
the fall in BMD is much steep as compared to chemo amenorrhea arm, however 
BMD improved significantly once GnRH was stopped, while it continued to 
detoriate in chemotherapy arm14.  An interesting hypothesis was proposed by 
Charles LS et al, that women who experience chemotherapy-induced ovarian 
failure develop rapid and highly significant decrease in BMD in the spine and 
femur, detectable with in 6 months post treatment. This is akin to surgical or 
medical ovarian ablation with rapid decrease in estrogen level, rather than natural 
menopause where estrogen levels wax and wane and decline over several years15. 
 
 
 
 
 
 
 
 
 
 
 
                          CONCLUSION 
 
                       CONCLUSION 
 
 
 
 
9 The bone mineral density among young patients with breast cancer was 
significantly poorer as compared to matched controls. 
9 Bone mineral density continued to fall with increasing age of the patient 
and increasing duration of ovarian insufficiency. 
9 There was no significant difference in BMD between patients who 
underwent castration or had chemo amenorrhea. 
9 There was no significant difference in BMD among patients with 
different chemotherapy schedules. 
9 Antiestrogens did not significantly affect bone health of patients. 
9 Interventions to reduce bone loss as well as long-term follow up studies 
are needed in women undergoing castration or chemo amenorrhea. 
9 Routine and regular assessment of the osteoporosis risk is warranted in 
the management of women with breast cancer.  
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                                      PROFORMA 
 
PROFORMA 
 
 
 
 
NAME -                                                                         WEIGHT -          kg  
AGE -                                                                             HEIGHT -           cm 
OP. NO -                                                                        BMI      -        kg / m2 
DIAGNOSIS -                                                               BMD        -   
STAGE -  
DATE OF DIAGNOSIS -   
AGE AT DIAGNOSIS -  
TREATMENT RECEIVED  
 
1. CHEMOTHERAPY - CMF / FAC / OTHERS  
2. SURGERY - BCS / MRM  
3. RADIOTHERAPY -             GY 
 
TREATMENT COMPLETED ON  
 
ANTIESTROGENS – TAMOXIFEN / ANASTRAZOLE / LETROZOLE  
 
     1.) RECEIVED FROM                                    TO 
      2.) DURATION 
 
H/O FRACTURE - YES / NO                                            IF YES AGE -   
FAMILY HISTORY OF FRACTURE – YES / NO           IF YES, AGE -   
CASTRATION DONE – YES / NO                                    IF YES  
(Surgical / radiation / medical) 
1. AGE    2. Date 
CHEMO AMENORRHEA - YES / NO 
 INVESTIGATIONS 
 
1. HEMOGLOBIN - 
2. TOTAL COUNT -  
3. PLATELETS -  
4. RANDOM BLOOD SUGAR -    
5. BLOOD UREA -   
6. SERUM CREATININE -  
7. TOTAL BILIRUBIN -   
8. SGOT -  
9. SGPT -   
 
MEDICATIONS 
 
1. CALCIUM SUPPLEMENTS - YES / NO  
2. OCP - YES / NO  
3. BISPHOSPHONATES - YES / NO   
 
DIET 
 
1. EGG - YES / NO 
2. MILK – YES / NO      
 
